Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00654
|
|||||
| Drug Name |
Moxalactam
|
|||||
| Synonyms |
(6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid; Disodium Moxalactam; Festamoxin; LMOX; Lamoxactam; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum; Latamoxefum [INN-Latin]; Lilly 127935; Ly127935; Moxalactam; Oxa-cephem; S-6059; Sid 734787
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H20N6O9S
|
|||||
| Canonical SMILES |
CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O
|
|||||
| InChI |
InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
|
|||||
| InChIKey |
JWCSIUVGFCSJCK-CAVRMKNVSA-N
|
|||||
| CAS Number |
CAS 64952-97-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 520.5 | Topological Polar Surface Area | 232 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 13 | |||
| XLogP |
-0.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103269737
, 104353085
, 11336084
, 11361323
, 11363865
, 11366427
, 11368989
, 11371639
, 11373726
, 11377151
, 11462295
, 11466847
, 11467967
, 11484790
, 11486374
, 11488883
, 11490326
, 11491879
, 11494785
, 117480923
, 117600506
, 124766432
, 126685470
, 128336018
, 134224607
, 134338426
, 134339083
, 135008052
, 135113257
, 137248766
, 137267739
, 14787236
, 15060840
, 34712479
, 46505546
, 47291366
, 47589221
, 48035393
, 48035394
, 48334770
, 48416297
, 49999588
, 57313109
, 625391
, 79526212
, 7980019
, 8180244
, 87299857
, 9440
, 96024799
|
|||||
| ChEBI ID |
CHEBI:599928
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | |
| References | ||||||
| 1 | Moxalactam was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.